Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNU6-175P** is a **pseudogene of the U6 small nuclear RNA (snRNA) gene family**, specifically identified as "RNA, U6 small nuclear 175, pseudogene." U6 snRNAs are essential non-coding RNAs that form a core component of the spliceosome, the molecular machinery responsible for intron removal from pre-mRNA in eukaryotic cells[1][2]. U6 pseudogenes, like RNU6-175P, are produced primarily by retrotransposition processes and do not produce mature, functional RNA products[3]. These pseudogenes lack the biological activities associated with canonical U6 snRNA and are generally considered non-functional genomic elements. As such, **RNU6-175P is not a therapeutic target, is not associated with diseases or drug action, and does not have known biomarker or safety implications**. Identification of multiple U6 pseudogenes in the human genome reflects the evolutionary history and retrotransposition dynamics of snRNA loci, but does not confer functional or clinical significance[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 175, pseudogene (RNU6-175P).